Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients

Atkinson, Wendy; Catana, Ciprian; Abramson, Jeremy S.; Arabasz, Grae; McDermott, Steven; Catalano, Onofrio A.; Muse, Victorine V.; Blake, Michael A.; Barnes, Jeffrey A.; Shelly, Martin J.; Hochberg, Ephraim P.; Rosen, Bruce R.; Guimarães, Alexander R.

doi:10.1007/s00261-016-0638-6

Cited by 54 publications

(31 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the PET-MR reconstruction software, approved for clinical use worldwide, automatically corrects for the delay between the time of FDG injection and the time of PET data acquisition for each bed position. Moreover, several studies have demonstrated comparable SUV values between PET-CT and subsequently acquired PET-MR (Pace et al , 2014; Atkinson et al , 2016; Pujara et al , 2016). …”

Section: Discussionmentioning

confidence: 93%

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background:Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes.Methods:21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR. Magnetic resonance-perfusion biomarkers, apparent diffusion coefficient (ADC), and standard uptake value (SUV) were compared with IHC markers and phenotypes, using a Student's t-test and one-way ANOVA.Results:ER/PR− tumours demonstrated higher Kepmean and SUVmax than ER or PR+ tumours. HER2− tumours displayed higher ADCmean, Kepmean, and SUVmax than HER2+tumours. Only ADCmean discriminated Ki67⩽14% tumours (lower ADCmean) from Ki67>14% tumours. PET/MR biomarkers correlated with IHC phenotype in 13 out of 21 patients (62% P=0.001).Conclusions:Positron emission tomography magnetic resonance might non-invasively help discriminate IDC phenotypes, helping to optimise individual therapy options.

show abstract

Section: Discussionmentioning

confidence: 93%

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The PET/MR reconstruction software automatically corrects for incubation time for each bed position. Moreover, several studies have demonstrated comparable performance between PET/CT and subsequently acquired PET/MR as quantified by SUV measurements (22,44,45).…”

Section: Discussionmentioning

confidence: 99%

Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast

Catalano

Daye

Signore

et al. 2017

International Journal of Oncology

Self Cite

View full text Add to dashboard Cite

The aim of the present study was to evaluate the performance of whole-body diffusion-weighted imaging (WB-DWI), whole-body positron emission tomography with computed tomography (WB-PET/CT), and whole-body positron emission tomography with magnetic resonance imaging (WB-PET/MRI) in staging patients with untreated invasive ductal carcinoma of the breast. Fifty-one women with newly diagnosed invasive ductal carcinoma of the breast underwent WB-DWI, WB-PET/CT and WB-PET/MRI before treatment. A radiologist and a nuclear medicine physician reviewed in consensus the images from the three modalities and searched for occurrence, number and location of metastases. Final staging, according to each technique, was compared. Pathology and imaging follow-up were used as the reference. WB-DWI, WB-PET/CT and WB-PET/MRI correctly and concordantly staged 33/51 patients: stage IIA in 7 patients, stage IIB in 8 patients, stage IIIC in 4 patients and stage IV in 14 patients. WB-DWI, WB-PET/CT and WB-PET/MRI incorrectly and concordantly staged 1/51 patient as stage IV instead of IIIA. Discordant staging was reported in 17/51 patients. WB-PET/MRI resulted in improved staging when compared to WB-PET/CT (50 correctly staged on WB-PET/MRI vs. 38 correctly staged on WB-PET/CT; McNemar's test; p<0.01). Comparing the performance of WB-PET/MRI and WB-DWI (43 correct) did not reveal a statistically significant difference (McNemar test, p=0.14). WB-PET/MRI is more accurate in the initial staging of breast cancer than WB-DWI and WB-PET/CT, however, the discrepancies between WB-PET/MRI and WB-DWI were not statistically significant. When available, WB-PET/MRI should be considered for staging patient with invasive ductal breast carcinoma.

show abstract

“…101,102 It follows that the combination of whole body MRI with DWI and FDG PET would offer the advantages of both technologies while minimizing radiation dose to these patients, many of whom require serial follow-up examinations over a long period of time. To this end, several studies have compared PET/MRI with PET/CT in the evaluation of lymphoma, showing high concordance between staging and comparable SUVmax measurements using both modalities in adult [103][104][105] and pediatric patients. 106,107…”

Section: Pelvicmentioning

confidence: 99%

PET/MRI: Where might it replace PET/CT?

Ehman

Johnson

Villanueva-Meyer

et al. 2017

Magnetic Resonance Imaging

195

137

View full text Add to dashboard Cite

Simultaneous positron emission tomography and MRI (PET/MRI) is a technology that combines the anatomic and quantitative strengths of MR imaging with physiologic information obtained from PET. PET and computed tomography (PET/ CT) performed in a single scanning session is an established technology already in widespread and accepted use worldwide. Given the higher cost and complexity of operating and interpreting the studies obtained on a PET/MRI system, there has been question as to which patients would benefit most from imaging with PET/MRI versus PET/CT. In this article, we compare PET/MRI with PET/CT, detail the applications for which PET/MRI has shown promise and discuss impediments to future adoption. It is our hope that future work will prove the benefit of PET/MRI to specific groups of patients, initially those in which PET/CT and MRI are already performed, leveraging simultaneity and allowing for greater degrees of multiparametric evaluation.

show abstract

Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients

Cited by 54 publications

References 49 publications

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype

Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast

PET/MRI: Where might it replace PET/CT?

Contact Info

Product

Resources

About